Company profile

Hummingbird Bioscience

Privately held: no public share price (Private Amgen/Novo Holdings-backed clinical-stage biotech; $125M Series C in 2021, has not listed as of Aug 2026. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.fiercebiotech.com/biotech/hummingbird-bioscience-buzzes-150m-series-c-led-by-novo-holdings]) · Singapore

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
ENV-501
Phase 2
HER3Antibody–drug conjugate
Non-Small Cell Lung Cancer
HMBD-001
Phase 2
HER3Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.